• Miscellaneous ocular agents

Lucentis Generic Name & Formulations

General Description

Ranibizumab 6mg/mL (0.3mg), 10mg/mL (0.5mg); soln for oph intravitreal inj; preservative-free.

Pharmacological Class

Vascular endothelial growth factor (VEGF) inhibitor.

How Supplied

Single-use prefilled syringe, single-use vial—1


Generic Availability


Lucentis Indications


Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).

Lucentis Dosage and Administration


Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.


Not established.

Lucentis Contraindications


Ocular or periocular infections.

Lucentis Boxed Warnings

Not Applicable

Lucentis Warnings/Precautions


Monitor intraocular pressure prior to and 30mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy; may cause embryo-fetal toxicity. Nursing mothers.

Lucentis Pharmacokinetics

See Literature

Lucentis Interactions

Lucentis Adverse Reactions

Adverse Reactions

Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events (with DME, DR).

Lucentis Clinical Trials

See Literature

Lucentis Note

Not Applicable

Lucentis Patient Counseling

See Literature